Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to…